Cabaletta Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Cabaletta Bio

16/05/2025 19:16

Cabaletta Bio Inc CABA.OQ reported a quarterly adjusted loss of 71 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -51 cents.  The mean expectation of eight analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -70 cents to -60 cents per share.

Reported revenue was zero​; analysts expected zero.

Cabaletta Bio Inc's reported EPS for the quarter was a loss of 71 cents​.

The company reported a quarterly loss of $35.94 million.

Cabaletta Bio Inc shares had risen by 30.7% this quarter and lost 20.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cabaletta Bio Inc is $15.00

This summary was machine generated from LSEG data May 16 at 06:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.64
-0.71
Missed
Dec. 31 2024
-0.63
-0.65
Missed
Sep. 30 2024
-0.60
-0.62
Missed
Jun. 30 2024
-0.55
-0.56
Missed